Orexo AB (publ) (ORXOF)
| Previous close | 4.0244 |
| Open | 4.0244 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 4.0244 - 4.0244 |
| 52-week range | 4.0244 - 6.1000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 138.016M |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions.
- PR Newswire
Orexo provides information about its new proprietary drug delivery platform - amorphOXTM
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a novel and inventive powder-based technology with significant potential. Several new patent applications directed to amorphOXTM have now been filed, which should serve to protect the technology until 2042.
- PR Newswire
Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully completed the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The study met its primary endpoints with naloxone exposure within the targeted interval. OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosing with the injection reference product. Furthermore, OX124 was found to be well tolerated. Based on the successful outcome of t
